Precision oncology works best when it links a real tumor feature to a real action: a targeted drug, an immunotherapy strategy, a trial option, a monitoring plan, or a reason not to treat. AI is useful here because the evidence now spans sequencing, pathology slides, radiology, blood tests, molecular residual disease signals, and long clinical histories that are difficult to synthesize manually at modern scale.
The strongest current systems are not replacing oncologists with one opaque score. They are helping teams rank targets, predict treatment benefit from multimodal evidence, turn scans into biomarkers through radiomics, monitor response with liquid biopsy, and search trials or care pathways more systematically. In all of those settings, good labels, external validation, and clear clinical context still matter more than model novelty alone.
This update reflects the field as of March 18, 2026 and leans mainly on Nature, Nature Medicine, recent PubMed-indexed studies, and clinically grounded program evaluations. Inference: the biggest near-term gains are better patient selection and faster adaptation of existing therapies, not autonomous cancer treatment planning.
1. Identifying Novel Therapeutic Targets
AI is improving target discovery by combining single-cell data, pathway analysis, drug-proximity mapping, and structural biology into one ranking workflow. That matters because modern oncology does not suffer from a lack of candidate alterations. It suffers from too many weak leads and not enough ways to prioritize which ones are actually druggable or therapeutically relevant.
A 2026 systems-level study in clear-cell renal cell carcinoma integrated single-cell transcriptomics, protein-interaction networks, and drug-target proximity to recover known vulnerabilities and surface underused targets such as ABL1, CDK4/6, and JAK signaling, with several FDA-approved compounds outperforming standard therapies in preclinical screens. A separate 2025 SCAN-ACT study used single-cell transcriptomics to prioritize CAR-T, bispecific, and TCR-T targets across solid tumors while explicitly checking tumor-versus-normal expression. Inference: the strongest discovery pipelines now connect biology to tractable intervention options instead of stopping at long gene lists.
2. Predicting Treatment Response
Treatment-response prediction is getting more useful when models are attached to a specific therapy decision and built from data clinicians already collect. Instead of asking AI to guess whether a patient has “good” or “bad” cancer in the abstract, precision oncology models increasingly ask a narrower and more actionable question: who is more likely to benefit from this regimen, and who is less likely to benefit enough to justify the risk.
Nature Medicine's SCORPIO model used routine blood tests and clinical data from 9,745 immune-checkpoint-inhibitor-treated patients across 21 cancer types and outperformed tumor mutational burden and PD-L1 alone for predicting benefit. In a separate phase III urothelial-cancer analysis, a multimodal AI biomarker predicted which patients were more likely to benefit from adjuvant immunotherapy in the IMvigor010 trial. Inference: response models become clinically credible when they sharpen a real treatment tradeoff using evidence that can be reproduced outside one center.
3. Drug Repositioning
AI-driven drug repositioning is attractive in oncology because it can search for anti-cancer effects in already approved molecules with known manufacturing and safety histories. That does not make repurposing easy, but it does mean a good model can reduce the time spent chasing implausible compounds and focus teams on candidates with pathway logic and experimental support.
A 2025 study on personalized prediction of anticancer potential in non-oncology drugs learned from genome-derived molecular pathways and paired model outputs with experimentally testable explanations. The 2026 renal-cancer systems study likewise showed how AI can map underused approved agents back onto tumor-specific vulnerabilities instead of treating repurposing as a blind screening exercise. Inference: repurposing is strongest when the model provides a mechanism-aware shortlist rather than a generic probability score.
4. Optimizing Combination Therapies
Combination therapy remains one of the hardest practical problems in precision oncology because the number of plausible drug pairs or triplets grows far faster than wet-lab testing capacity. AI helps by learning which combinations are most likely to be synergistic, which ones are likely to be redundant, and which should be tested first in a specific disease context.
A 2025 study in pancreatic cancer reported 307 experimentally validated synergistic drug combinations after AI-guided screening, including 26 strongly synergistic pairs, which is exactly the kind of narrowing that makes combination work tractable. Inference: the best current role for AI is not declaring a final regimen by itself, but compressing a vast combinatorial search into a much smaller queue worth real experimental and clinical attention.
5. Radiomics and Imaging Biomarkers
Imaging is already embedded in cancer care, so AI-derived imaging biomarkers are valuable when they extend the information available from routine scans without requiring another invasive procedure. That is where radiomics and newer imaging foundation models matter: they can turn scans into quantitative features that correlate with response, progression, or molecular state.
A 2024 Nature Medicine study showed how a foundation model for cancer imaging biomarkers can extract reusable quantitative imaging signals, while a 2025 multimodal deep-learning study linked image-derived information to PD-L1 prediction and immunotherapy outcomes in esophageal cancer. Inference: imaging biomarkers are strongest when they are evaluated against a defined endpoint such as biomarker status or treatment benefit, not presented as a universal shortcut around tissue and molecular testing.
6. Prognostic and Predictive Modeling
Modern prognosis in oncology is moving away from single-modality scores and toward models that combine pathology, longitudinal care history, genomics, and treatment context. Those richer models are more useful because survival and recurrence are shaped not just by tumor biology, but also by where disease spread was documented, what therapies were given, and how a patient actually moved through care.
A 2025 Nature Communications study focused directly on generalizable cancer diagnosis and survival prediction from histopathological images, while Nature's MSK-CHORD resource showed that outcome models improved when natural-language-derived oncology variables were added to structured clinico-genomic data from 24,950 patients. Inference: prognosis gets stronger when models see the care trajectory and not just a baseline stage label or mutation list.
7. Real-Time Treatment Adaptation
The strongest current evidence for AI-assisted treatment adaptation comes from systems that react to serial measurements such as liquid biopsy signals or online radiotherapy replanning data. That is a more grounded use of AI than the older idea of a fully autonomous dosing agent because the model is constrained by clinically interpretable triggers and expert oversight.
In advanced non-small cell lung cancer, a nonrandomized controlled trial of ctDNA-guided de-escalation of targeted therapy reported a median progression-free survival of 18.4 months together with a median treatment break of 9.1 months. In cervical cancer, a 2025 AI system for online adaptive radiotherapy decision support reached an AUC of 0.917 and outperformed physician consensus on accuracy in an independent evaluation. Inference: real-time adaptation is becoming clinically plausible where AI is bounded by concrete molecular or imaging checkpoints.
8. High-Throughput Genomic Data Analysis
Precision oncology no longer means reading one hotspot panel by hand. It increasingly means ranking information from panel sequencing, whole-transcriptome data, single-cell assays, and multi-omics studies in a way that connects findings to actionability. AI is useful because it can sort high-dimensional data into clinically meaningful priorities faster than manual review and with more consistent structure.
SCAN-ACT is a good example of high-throughput analysis with a therapeutic endpoint because it uses single-cell and multi-omics evidence to prioritize immunotherapy targets rather than simply clustering cells. At health-system scale, the decade-long VHIO precision medicine program showed what mature analysis pipelines can deliver operationally: actionable alterations increased from 10.1% in 2014 to 53.1% in 2024 as assays and biomarker evidence expanded. Inference: genomic scale only matters when the interpretation layer converts raw findings into usable actionability frameworks.
9. Automated Clinical Trial Matching
Automated trial matching is one of the most practical precision-oncology uses for AI because modern protocols combine biomarker criteria, disease stage, therapy history, organ function thresholds, and local trial availability in ways that are easy to miss manually. The technology is useful, but the latest ground truth also shows its limits very clearly.
A 2025 randomized trial of AI-triggered trial notifications in precision oncology did not show a statistically significant increase in enrollment rate, which is an important correction to overhyped claims. A separate prospective evaluation in a molecular tumor board found that automatic matching tools increased available trial options by 26%, but precision and recall remained modest, with gene-variant interpretation as a recurring failure point. Inference: current trial-matching systems are best used to widen search and reduce missed opportunities, not to replace expert eligibility review.
10. Intelligent Electronic Health Records (EHR) Utilization
Oncology decisions depend heavily on longitudinal history that lives in the electronic health record: prior regimens, toxicity, imaging interpretations, sites of disease, progression timing, and comorbidities. AI helps by turning messy records into structured variables and by supporting privacy-conscious collaboration patterns such as federated learning when institutions cannot freely centralize raw patient data.
Nature's MSK-CHORD resource harmonized medications, demographics, tumor registry data, genomics, and natural-language-derived annotations from 24,950 patients across major cancer types. In that setting, models that included NLP-derived features such as sites of disease outperformed models based only on genomic data or stage, and large-scale annotation of radiology reports uncovered metastasis patterns that smaller datasets missed. Inference: EHR AI is most valuable when it creates clinically reusable longitudinal context rather than pretending the chart is already a clean research table.
11. Pathology Image Analysis
Pathology AI is becoming more useful as it shifts from narrow slide classifiers to reusable computational pathology representations. That matters in precision oncology because whole-slide images are one of the richest and most scalable visual records of tumor state, and they can now contribute to diagnosis, prognosis, biomarker prediction, and trial stratification.
Virchow, a clinical-grade computational pathology foundation model, showed that large pretraining on digitized slides can support strong performance across common and rare cancers, including out-of-distribution settings. A 2025 Nature Communications study pushed the same direction toward diagnosis and survival prediction from histopathology. Inference: slide AI is strongest as a measurement layer that augments pathologists and downstream models, especially when paired with computer vision workflows designed for whole-slide scale and cross-site variability.
12. Modeling Intratumoral Heterogeneity
One reason targeted therapies and immunotherapies fail is that tumors are not uniform. They contain subclones, immune niches, and spatially distinct cell states that bulk assays can blur away. AI helps quantify that heterogeneity so clinicians and researchers can ask not only whether a marker exists, but where it lives, how consistent it is, and whether it is linked to clinically relevant escape routes.
A 2025 integrative spatial analysis in small-cell lung cancer linked intratumoral heterogeneity and immune colony niches to clinical outcomes, showing how local architecture can matter as much as bulk abundance. SCAN-ACT adds the same logic on the single-cell side by ranking targets while checking tumor and normal tissue expression. Inference: heterogeneity modeling is clinically valuable when it clarifies whether a proposed target or biomarker is stable enough to guide intervention across the actual tumor landscape.
13. Advanced Molecular Modeling
Structural AI is making targeted-therapy discovery faster by helping teams move from a nominated target to a plausible molecular interaction model much earlier in the process. That is especially useful in oncology, where mutations, binding-pocket changes, and resistance-associated structural shifts can all affect whether a therapeutic idea is worth chemistry and assay effort.
AlphaFold 3 extended AI structure prediction beyond isolated proteins to biomolecular interactions, including protein-ligand and protein-nucleic-acid complexes. Combined with the AlphaFold Protein Structure Database, that gives oncology research teams a much faster way to check whether a nominated target and a candidate binder are structurally plausible before expensive wet-lab iteration. Inference: the real advance is faster, better-ranked hypothesis triage for drug discovery, not the elimination of medicinal chemistry or experimental pharmacology.
14. Predicting Resistance Mechanisms
Resistance prediction becomes useful when it moves from a one-time baseline guess to longitudinal surveillance of how tumors change under therapy. In practice that means combining serial blood-based molecular measurements, treatment history, and tumor-context features so clinicians can detect escape earlier and plan a switch before radiographic progression becomes obvious.
The ctDNA-guided NSCLC de-escalation study is one concrete example of resistance-aware monitoring because serial molecular signals were used to adapt targeted therapy rather than waiting for later clinical deterioration. A separate 2025 study in metastatic clear-cell renal cell carcinoma reported a multimodal algorithm that predicted treatment response and survival from the cell of origin and immunogenomic landscape, which is the direction resistance modeling is heading more broadly. Inference: the next generation of resistance prediction will likely be longitudinal and multimodal, not a single baseline biomarker readout.
15. Microbiome-Cancer Interaction Analysis
Microbiome work in oncology is still exploratory, but AI helps by testing whether metagenomic patterns add predictive value around treatment response, especially for immunotherapy. The important ground truth is that this field is promising yet not settled: signal exists, but reproducibility across cohorts remains a major issue.
A 2025 cross-cohort metagenomic analysis in lung cancer integrated 209 fecal samples and used machine learning to differentiate responders from non-responders to immune checkpoint therapy, identifying Bacteroides caccae and Prevotella copri as candidate biomarkers. Inference: microbiome AI is best viewed today as a stratification and mechanism-discovery tool, not as a routine stand-alone basis for treatment selection.
16. Cost-Effective Biomarker Discovery
One of the most important practical goals in precision oncology is finding biomarkers that do not require every patient to undergo maximal testing. AI helps here by extracting more predictive value from routine blood tests, targeted blood assays, or smaller feature sets so that precision methods can scale beyond highly resourced centers.
SCORPIO is a strong example because it showed that routine blood tests plus basic clinical variables could outperform more established but harder-to-deploy biomarkers for some immunotherapy decisions. Separate 2024 work on cfDNA methylation in ovarian cancer used transformer-based modeling to improve signal extraction from blood-based assays. Inference: cost-effective biomarker discovery is strongest when AI is used to squeeze more decision value out of tests that health systems can realistically repeat and validate.
17. Population-Level Insights
Precision oncology is not only about one patient at a time. It also depends on program-scale learning about which alterations are actionable, how often matched therapies are actually delivered, and where evidence gaps or access gaps remain. AI and large harmonized datasets make that population view more practical.
The decade-long VHIO precision medicine program analyzed 13,718 molecular profiles from 12,168 patients and found that matched targeted-therapy use increased from 1% in 2014 to 14.2% in 2024 as genomic actionability rose and supporting evidence matured. Inference: at population level, the main challenge is no longer generating molecular data alone. It is converting more findings into validated, accessible care pathways, trials, and reimbursement reality.
Sources and 2026 References
- Nature npj Drug Discovery: Machine learning-guided discovery of therapeutic targets and repurposable therapeutics for clear-cell renal cell carcinoma
- PubMed: SCAN-ACT adoptive T cell therapy target discovery through single-cell transcriptomics
- Nature Medicine: Prediction of checkpoint inhibitor immunotherapy efficacy for cancer using routine blood tests and clinical data
- PubMed: A multimodal AI model predicts efficacy of adjuvant immunotherapy in high-risk muscle-invasive urothelial carcinoma from the IMvigor010 phase III trial
- PubMed: Personalized prediction of anticancer potential of non-oncology drugs through learning from genome-derived molecular pathways
- PubMed: Artificial intelligence-driven discovery of synergistic drug combinations against pancreatic cancer
- PubMed: A foundation model for cancer imaging biomarkers
- PubMed: Multimodal deep learning for predicting PD-L1 biomarker and clinical immunotherapy outcomes of esophageal cancer
- Nature Communications: A foundation model for generalizable cancer diagnosis and survival prediction from histopathological images
- Nature: Automated real-world data integration improves cancer outcome prediction
- PubMed: Circulating tumor DNA-guided de-escalation targeted therapy for advanced non-small cell lung cancer
- PubMed: AI-assisted online adaptive radiation therapy decision-making for cervical cancer
- Nature Medicine: Virchow, a million-slide digital pathology foundation model
- PubMed: Integrative spatial analysis reveals high intratumoral heterogeneity and immune colony niche related to clinical outcomes in small-cell lung cancer
- Nature: Accurate structure prediction of biomolecular interactions with AlphaFold 3
- AlphaFold Protein Structure Database
- PubMed: Multimodal algorithm predicts treatment response and survival outcomes in metastatic clear-cell renal cell carcinoma
- PubMed: Exploring fecal microbiota signatures associated with immune response and antibiotic impact in NSCLC
- PubMed: Transformer-based AI technology improves early ovarian cancer diagnosis using cell-free DNA methylation markers
- PubMed: Clinical Trial Notifications to Increase Enrollment of Patients With Cancer in Precision Oncology Trials
- PubMed: A prospective pragmatic evaluation of automatic trial matching tools in a molecular tumor board
- PubMed: Genomic actionability and matched targeted therapy in a decade-long institutional precision medicine program for solid tumors
Related Yenra Articles
- Biomarker Discovery in Healthcare covers the upstream search for response, monitoring, and validation signals that later feed precision oncology.
- Cancer Treatment Planning shows how biomarker and disease-state information gets translated into practical care decisions.
- Personalized Medicine broadens the same logic beyond oncology into individualized care more generally.
- Clinical Trial Management adds more context on how patient matching and protocol operations intersect in modern cancer research.